Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Non-Deal Roadshow (July 2024)
29 slides from Optiscan Imaging's roadshow presentation, Jul 1, 2024
Slide 1: Optiscan 2024 Roadshow Presentation
ASX Announcement 1 July 2024 (Melbourne, Australia) Optiscan Imaging Ltd (ASX:OIL) Optiscan 2024 Roadshow Presentation Optiscan is today commencing an investor roadshow, where the Company will be highlighting both its recent achievements and development strategy milestones expected to be delivered o
Slide 2: About Optiscan
About Optiscan Optiscan Imaging Ltd (ASX:OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the d
Slide 3: The new standard in digital pathology and precision surgery
The new standard in digital pathology and precision surgery Optiscan Imaging Ltd (ASX:OIL) Investor Roadshow 1st – 3rd July, 2024
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 1 July 2024. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor ma
Slide 5: Presenter
Presenter Dr Camile Farah MBA, PhD, MAICD, FAIM, FLWA CEO & Managing Director, Optiscan Imaging Ltd (ASX:OIL) President & CEO, Optiscan Imaging, Inc. cfarah@optiscan.com /company/Optiscan www.optiscan.com
Slide 6: Optiscan at a Glance
Optiscan at a Glance A global medical technology company leading the transformation of digital pathology and precision surgery ASX: OIL Melbourne $ 175m Patent Proven Validated Team 2,350 m2 QMS Minnesota 1997 Headquarters Market Cap Protected Technology Products Agile Office & Plant Certification C
Slide 7: Revolutionizing Diagnostics
Revolutionizing Diagnostics Optiscan is a global medical technology company focused on real-time digital pathology and precision surgery solutions. o Disruptive Technology: Miniaturised digital endomicroscope with spatial resolution more than 1000x that of medical CT and MRI to enable live optical b
Slide 8: Growing product range across critical care
Growing product range across critical care Clinical Product Family Vision Oral Cervical Surgical Pathology GI Vet + Developing a Full Suite of Digital Health Assets Intraoperative Telepathology & Remote AI Based Identification Biopsy Channel Compatible Integration with Robotics Image-guided Diagnost
Slide 9: Unique patent protected technology
Unique patent protected technology Process Result o Topical or IV o Fluorescence intensity variations are fluorescent contrast mapped, creating real-time digital dye applied to tissue microscopic images of interest o Up to 1000x magnification - subcellular o A single optical fibre level detail (0.55
Slide 10: Unparallelled precision
Unparallelled precision Technology Image – Mouse Ilium Comparison Single fibre Whole imaging plane is scanned No blank spots, all critical clinical information displayed No image processing, stitching or mosaicking required Sub-micron optical resolution with optimal image sampling Z-stac
Slide 11: Customer Validation: Positive, Enthusiastic Feedback
Customer Validation: Positive, Enthusiastic Feedback User Testimonials Media Coverage Prof. Mark C. Preul Neurosurgeon, Newsome Chair of Neurosurgery Research, Barrow Neurosurgical Institute, Arizona, USA “This probably is the most exciting technology that I have seen in my career come through the l
Slide 12: Market opportunity
Market opportunity
Slide 13: Significant market demand
Significant market demand Life sciences Financial pressures Workflow Demand Ethical testing inefficiencies for accelerated drug • Reduced R&D • Ethical development budgets: Pharmaceutical • Traditional pre-clinical Considerations: companies and research research methods can • Reproducibility of Ther
Slide 14: Addressing the massive health challenge of cancer
Addressing the massive health challenge of cancer High, growing Cancer treatment Frozen section Access to quality Traditional healthcare is cancer rates are a lacks accuracy and procedure is time- histopathology is disperse and varies Challenge huge burden on results in high consuming, costly not in
Slide 15: Current Clinical Applications: Large, Relevant Markets
Current Clinical Applications: Large, Relevant Markets Cancer Cases Healthcare Spend 100 50k Optiscan Focus Areas 80 30% 1.5m 60 3.6m 40 Others 70% 20 0 Gastrointestinal (GI) Breast Head / Neck Total US Cancer Cases Optiscan Focus Areas US Healthcare Spend (16.7m) (5.75m) (US$ 160bn) Optiscan’s curr
Slide 16: Larger Opportunity Ahead of Us
Larger Opportunity Ahead of Us To date, Optiscan has focused on a portion of the healthcare market opportunity. The digital health space presents a sizeable and lucrative opportunity for future growth. THE OPPORTUNITY The global AI The global digital healthcare market health market is size was estim
Slide 17: Positioned for growth
Positioned for growth Phase 1: Core foundation Phase 2: Strategic transformation Phase 3: Strategic growth o Strategic focus o Digital health solutions o Develop core platform leader and initial product o Optimised operations offering o Full suite of digital health o Investment in growth products o
Slide 18: A strategic step into the future
A strategic step into the future o Optiscan has entered into a know-how agreement with Mayo Clinic - the largest integrated, not-for-profit medical group practice in the world. o Mayo Clinic’s collaboration with Optiscan demonstrates the legitimacy and clinical application of our technology and prod
Slide 19: The next evolution in Precision Surgery
The next evolution in Precision Surgery o Optiscan recently unveiled InVue - a next-gen microscopic medical imaging device for precision surgery. o InVue expands Optiscan’s product portfolio into the surgical market, representing a significant step forward in realizing the Company’s strategic goals.
Slide 20: Financials
Financials
Slide 21: Experienced Leadership
Experienced Leadership Camile Farah Robert Cooke Sean Gardiner Karen Borg Ron Song President & CEO Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Board Management Brendan Fafiani Sanchitha Fernando Darius Ooi Shayra Leon Tim Rowe COO CTO Finance BDM US We
Slide 22: Corporate overview
Corporate overview o Investment Opportunity: Disrupting a Multi-Billion Dollar o ASX: OIL Market o Listing: 8th August, 1997 o Share price: $0.225 o Large Addressable Market: High growth segments – medical research, pharmaceuticals, oncology, pathology, GI diseases o Market capitalization: $175.42M
Slide 23: Financial Summary
Financial Summary Financial Position Projected Revenue 15 Cash & term deposits $12.2 m 10 Current assets $15.3 m Million 5 Current liabilities $1.2 m 0 Working capital $14.1 m -5 Y1 Y2 Y3 Y4 Y5 Revenue Net Profit Top Shareholders Capital Allocation 1% 1% 25.7 R&D 50.3 Production & operations 44% 19.
Slide 24: Outlook
Outlook
Slide 25: Strategic Growth – Product Development
Strategic Growth – Product Development Application Stage Collaborator Oral IDEATION PROTOTYPING PRECLINICAL CLINICAL REGULATORY LAUNCH MONITORING Breast IDEATION PROTOTYPING PRECLINICAL CLINICAL REGULATORY LAUNCH MONITORING Pathology IDEATION PROTOTYPING PRECLINICAL CLINICAL REGULATORY LAUNCH MONITO
Slide 26: Optiscan's Growing Footprint & Sales Pipeline
Optiscan’s Growing Footprint & Sales Pipeline Rochester, United States Regional Office Clinical & Regulatory Affairs European Union Business Development Sales & Marketing Beijing, China Chicago, United States Distribution Business Development Sinsi Technologies Ltd Sales & Marketing Portland, United
Slide 27: Continuing the Momentum
Continuing the Momentum o Optiscan has pivoted from an early-stage OEM provider to a strategically focused, diversified, and optimized business. o The foundation we have laid positions us for legitimate growth and a path to become a global innovator in digital health. o Our collaboration with Mayo C
Slide 28: Contact Us
Contact Us Shareholder & General Enquiries Media & Investor Enquiries Optiscan Imaging Ltd The Capital Network Dr Camile Farah Julia Maguire T: +61 3 9538 3333 T: +61 2 8999 3699 E: ceo@optiscan.com E: julia@thecapitalnetwork.com.au Visit us at optiscan.com Connect with us on LinkedIn X Instagram Fa
Slide 29: Optiscan
Optiscan”